ClinicalTrials.Veeva

Menu

RCT Versus Placebo of rTMSQP Over Visual Cortex for the Prevention of Chronic Migraine

U

University of Liege

Status

Withdrawn

Conditions

Chronic Migraine

Treatments

Device: Super Rapid Magstim Stimulator
Device: Super Rapid Magstim Stimulator (sham)

Study type

Interventional

Funder types

Other

Identifiers

NCT02122744
CB-1331

Details and patient eligibility

About

Evaluation of inhibiting rTMS QP over the visual cortex for the prevention of chronic migraine. The aim of the study is to confirm that inhibiting rTMS QP is capable to decrease the frequency of migraine and if its effect is stronger than placebo effect.

Full description

The investigators have already inquired if inhibiting rTMS QP over the visual cortex determines a reduction of frequency of migraine in a previous study. After 2 weekly sessions for a month, the investigators demonstrated a reduction of 47% in migraine frequency. In this study, the investigators aim to compare rTMS QP effect with the placebo effect and to evaluate if rTMS QP is capable to induce changes in VEP, CHEPS and QST.

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • diagnosis of chronic migraine (ICHD III beta 1.3) with or without medication overuse.

Exclusion criteria

  • other diseases or contraindication for the magnetic stimulation (epilepsy, pacemaker, metallic prothesis)

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

0 participants in 2 patient groups, including a placebo group

Super Rapid Magstim Stimulator rTMS QP
Active Comparator group
Description:
rTMS QP is delivered over the visual cortex for 30 minutes, 2 times a week for 8 weeks, in 15 patients
Treatment:
Device: Super Rapid Magstim Stimulator
Placebo
Placebo Comparator group
Description:
rTMS QP placebo (coil perpendicular to the scalp) is delivered over the visual cortex for 30 minutes, 2 times a week for 8 weeks, in 15 patients.
Treatment:
Device: Super Rapid Magstim Stimulator (sham)

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems